Abstract 192P
Background
Lung cancer is a disease that ranks among the first in incidence and mortality in Mexico and worldwide. Neuroendocrine tumors (NETs) have been studied for their neurological and endocrine characteristics; NETs are characterized by having active autocrine/paracrine communication with the microenvironment. Serotonin is precursor of melatonin, an indolamine that can exert immunomodulatory effects and is considered one of the molecules of the neuro-immuno-endocrine axis. The transmembrane protein death ligand 1 (PD-L1) is overexpressed in some types of cancer cells, giving them the ability to camouflage themselves against the immune system. The activation PD-1/PD-L1 are responsible for the proliferation, activation, and cytotoxic secretion of T cells in cancer to generate the antitumor immune response.
Methods
In this work neuroendocrine A549 cells were obtained by two different transdifferentiation methodologies for 72 hours with cAMP inducers in DMEM with 2% fetal bovine serum (NED2%) and without fetal bovine serum (NEDsSFB). This differentiation was corroborated through the evaluation of morphology by light microscopy and the expression of specific markers Chromogranin (CgA) and Synaptophysin (Syn) by rt-PCR. The expression of PD-L1 was assessed in A549 cells, NED2% and NEDsSFB groups by rt-PCR and flow cytometry. A co-culture was performed with the neuroendocrine models with T lymphocytes to observe the cytotoxic effect for 24 hours.
Results
The results showed a new neuroendocrine model, suggest an inhibitory effect in proliferation of melatonin and serotonin from concentrations of 2.5 mM and 0.5 μM respectively in both neuroendocrine models at 24 and 48 hours. It is confirmed for the first time the presence of PD-L1 in the neuroendocrine phenotypes cells of A549 (NED2% and NEDsSFB) and thus a mechanism for evasion of the immune system can be proposed.
Conclusions
We conclude with the development of a new neuroendocrine model as well as the possible mechanism of the decrease in the cytotoxic effect of T lymphocytes in neuroendocrine models.
Legal entity responsible for the study
Universidad Autónoma de Querétaro.
Funding
Universidad Autónoma de Querétaro Conahcyt.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
Resources:
Abstract
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
Resources:
Abstract
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
Resources:
Abstract
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
Resources:
Abstract
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
Resources:
Abstract
114P - Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS=5: Updated results from a real-world study
Presenter: Qi Xu
Session: Poster Display session
Resources:
Abstract
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
Resources:
Abstract
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
Resources:
Abstract
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
Resources:
Abstract
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session
Resources:
Abstract